Hawaii Chapter - NBDF
Phone 808-284-7417

Our Mission

The National Bleeding Disorders Foundation (NBDF) Hawaii Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing complications of these disorders through research, education, and advocacy enabling people and families to thrive.  

News Articles

Federal: 

 

Strong Support for FY27 Funding for Federal Bleeding Disorders Programs 

The National Bleeding Disorders Foundation (NBDF) is alerting the community to updated information from Takeda Pharmaceutical Company regarding the discontinuation timelines for HEMOFIL® M and RECOMBINATE®, two therapies used to treat hemophilia A, first announced last year.

The Neil Frick Resources Center (NFRC) is excited to announce new 2026 scholarship opportunities available to the bleeding disorders community.

CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), announced on March 17, 2026, a temporary global stockout of the therapy. This disruption means that some individuals in countries where HEMGENIX is commercially available may experience delays in accessing treatment.

View All

Resource Links

Hawaii Chapter - NBDF
75-5660 Kopiko Street, Suite C7 #294
Kailua-Kona, HI 96740
Phone 808-284-7417

© National Bleeding Disorders Foundation 2026

Crafted by Firespring